Cargando…
Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients
BACKGROUND: The outcome of colon cancer patients without lymph node metastasis is heterogeneous. Searching for new prognostic markers is warranted. METHODS: One hundred twenty stage I–II colon cancer patients who received complete surgical excision during 1995–2004 were selected for this biomarker s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chang Gung University
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138591/ https://www.ncbi.nlm.nih.gov/pubmed/28411881 http://dx.doi.org/10.1016/j.bj.2017.01.004 |
_version_ | 1783355358552522752 |
---|---|
author | Huang, Shih-Chiang Huang, Shiu-Feng Chen, Ya-Ting Chang, Yu Chiu, Yu-Ting Chang, Il-Chi Wu, Hong-Dar Isaac Chen, Jinn-Shiun |
author_facet | Huang, Shih-Chiang Huang, Shiu-Feng Chen, Ya-Ting Chang, Yu Chiu, Yu-Ting Chang, Il-Chi Wu, Hong-Dar Isaac Chen, Jinn-Shiun |
author_sort | Huang, Shih-Chiang |
collection | PubMed |
description | BACKGROUND: The outcome of colon cancer patients without lymph node metastasis is heterogeneous. Searching for new prognostic markers is warranted. METHODS: One hundred twenty stage I–II colon cancer patients who received complete surgical excision during 1995–2004 were selected for this biomarker study. Immunohistochemical method was used to assess p53, epidermal growth factor receptor, MLH1, and MSH2 status. KRAS mutation was examined by direct sequencing. RESULTS: Thirty three patients (27.5%) developed metachronous metastasis during follow up. By multivariate analysis, only female gender (p = 0.03), high serum carcinoembryonic antigen (CEA) level (≧5 ng/ml) (p = 0.04), and MLH1 overexpression (p = 0.003) were associated with the metastasis group. The 5-year-survival rate were also significantly lower for female gender (71.7% versus 88.9%, p = 0.025), high CEA level (64.9% versus 92.4%, p < 0.001), and MLH1 overexpression (77.5% versus 94.4%, p = 0.039). In contrast, MSH2 overexpression was associated with better survival, 95.1% versus 75.5% (p = 0.024). CONCLUSIONS: The reversed prognostic implications in the overexpression of MLH1 and MSH2 for stage I–II colon cancer patients is a novel finding and worthy of further confirmation. |
format | Online Article Text |
id | pubmed-6138591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Chang Gung University |
record_format | MEDLINE/PubMed |
spelling | pubmed-61385912018-09-27 Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients Huang, Shih-Chiang Huang, Shiu-Feng Chen, Ya-Ting Chang, Yu Chiu, Yu-Ting Chang, Il-Chi Wu, Hong-Dar Isaac Chen, Jinn-Shiun Biomed J Original Article BACKGROUND: The outcome of colon cancer patients without lymph node metastasis is heterogeneous. Searching for new prognostic markers is warranted. METHODS: One hundred twenty stage I–II colon cancer patients who received complete surgical excision during 1995–2004 were selected for this biomarker study. Immunohistochemical method was used to assess p53, epidermal growth factor receptor, MLH1, and MSH2 status. KRAS mutation was examined by direct sequencing. RESULTS: Thirty three patients (27.5%) developed metachronous metastasis during follow up. By multivariate analysis, only female gender (p = 0.03), high serum carcinoembryonic antigen (CEA) level (≧5 ng/ml) (p = 0.04), and MLH1 overexpression (p = 0.003) were associated with the metastasis group. The 5-year-survival rate were also significantly lower for female gender (71.7% versus 88.9%, p = 0.025), high CEA level (64.9% versus 92.4%, p < 0.001), and MLH1 overexpression (77.5% versus 94.4%, p = 0.039). In contrast, MSH2 overexpression was associated with better survival, 95.1% versus 75.5% (p = 0.024). CONCLUSIONS: The reversed prognostic implications in the overexpression of MLH1 and MSH2 for stage I–II colon cancer patients is a novel finding and worthy of further confirmation. Chang Gung University 2017-02 2017-03-14 /pmc/articles/PMC6138591/ /pubmed/28411881 http://dx.doi.org/10.1016/j.bj.2017.01.004 Text en © 2017 Chang Gung University. Publishing services by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Huang, Shih-Chiang Huang, Shiu-Feng Chen, Ya-Ting Chang, Yu Chiu, Yu-Ting Chang, Il-Chi Wu, Hong-Dar Isaac Chen, Jinn-Shiun Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients |
title | Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients |
title_full | Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients |
title_fullStr | Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients |
title_full_unstemmed | Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients |
title_short | Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I–II colon cancer patients |
title_sort | overexpression of mutl homolog 1 and muts homolog 2 proteins have reversed prognostic implications for stage i–ii colon cancer patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138591/ https://www.ncbi.nlm.nih.gov/pubmed/28411881 http://dx.doi.org/10.1016/j.bj.2017.01.004 |
work_keys_str_mv | AT huangshihchiang overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients AT huangshiufeng overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients AT chenyating overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients AT changyu overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients AT chiuyuting overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients AT changilchi overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients AT wuhongdarisaac overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients AT chenjinnshiun overexpressionofmutlhomolog1andmutshomolog2proteinshavereversedprognosticimplicationsforstageiiicoloncancerpatients |